Want to see SE:PROGEN full AI Analyst Report?
Top Page
Prostatype Genomics AB
(PROGEN)
Select Model
Select Model
Rating:45Neutral
Price Target:
kr0.15
▼(-79.47% Downside)
Action:Reiterated
Date:08/28/26
The score is held down primarily by weak financial performance (minimal/declining revenue, large ongoing losses, and sustained cash burn). Technicals are mixed with only short-term improvement against a longer-term downtrend. Valuation is not supportive due to negative earnings and no dividend.
Positive Factors
Positive equity cushion and moderate leverage
Positive equity and moderate leverage provide a financial cushion relative to the company’s losses. This may preserve some flexibility to fund commercialization and operations, although continued losses could reduce that cushion over time.
Negative Factors
Recent revenue decline
Recent revenue contraction indicates that commercial adoption of the prostate cancer testing offering remains insufficient or inconsistent. Sustained growth is needed to support operating leverage, validate market demand, and reduce dependence on external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive equity cushion and moderate leverage
Positive equity and moderate leverage provide a financial cushion relative to the company’s losses. This may preserve some flexibility to fund commercialization and operations, although continued losses could reduce that cushion over time.
Read all positive factors
Prostatype Genomics AB (PROGEN) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr91.36M
Dividend YieldN/A
Average Volume (3M)300.11K
Price to Earnings (P/E)―
Beta (1Y)-1.10
Revenue Growth198.49%
EPS Growth84.60%
CountrySE
Employees7
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-1.82
Shares Outstanding532,703,900
10 Day Avg. Volume460,844
30 Day Avg. Volume300,114
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.38
Price to Sales (P/S)17.06
P/FCF Ratio-0.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.08
Revenue Forecast (FY)kr1.23M
Prostatype Genomics AB Business Overview & Revenue Model
Company Description
Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason...
How the Company Makes Money
PROGEN primarily makes money by commercializing its prostate cancer prognostic testing offering to healthcare providers and/or clinical laboratories. Revenue is generated when the test is ordered for eligible patients and performed (either by PROG...
Prostatype Genomics AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 594.00K | 199.00K | 1.36M | 683.00K | 10.00K |
| Gross Profit | -37.62M | 1.92M | 3.73M | 683.00K | 2.51M |
| EBITDA | -36.89M | -37.40M | -38.02M | -26.79M | -15.46M |
| Net Income | -44.50M | -41.05M | -41.44M | -29.09M | -15.63M |
Balance Sheet | |||||
| Total Assets | 50.86M | 41.97M | 49.22M | 30.95M | 40.20M |
| Cash, Cash Equivalents and Short-Term Investments | 9.07M | 9.42M | 2.68M | 11.49M | 20.33M |
| Total Debt | 5.30M | 67.00K | 11.67M | 867.00K | 1.27M |
| Total Liabilities | 24.33M | 8.50M | 24.55M | 4.80M | 4.30M |
| Stockholders Equity | 26.53M | 33.47M | 24.67M | 26.15M | 35.91M |
Cash Flow | |||||
| Free Cash Flow | -24.06M | -52.57M | -37.70M | -27.69M | -18.58M |
| Operating Cash Flow | -23.80M | -44.71M | -29.14M | -27.69M | -16.08M |
| Investing Cash Flow | -13.36M | -8.36M | -8.57M | 0.00 | -2.50M |
| Financing Cash Flow | 36.83M | 59.75M | 28.91M | 18.85M | 23.05M |
Prostatype Genomics AB Technical Analysis
Positive
0.75
Price Trends
0.16
Positive
0.20
Negative
0.28
Negative
Market Momentum
>-0.01
Negative
58.30
Neutral
88.38
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PROGEN, the sentiment is Positive. The current price of 0.75 is above the 20-day moving average (MA) of 0.13, above the 50-day MA of 0.16, and above the 200-day MA of 0.28, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 58.30 is Neutral, neither overbought nor oversold. The STOCH value of 88.38 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:PROGEN.
Prostatype Genomics AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | kr128.80M | -1.21 | -81.76% | ― | 55.24% | 70.00% | |
52 Neutral | kr994.22M | 65.22 | ― | ― | 6.51% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | kr91.36M | -0.09 | -141.25% | ― | 198.49% | 84.60% | |
45 Neutral | kr95.92M | -0.85 | -853.71% | ― | 31.66% | 79.68% | |
43 Neutral | kr350.55M | -1.40 | -60.76% | ― | 79.55% | 90.21% | |
43 Neutral | kr278.02M | -7.06 | -106.02% | ― | 65.82% | 41.28% |
* Healthcare Sector Average
SE:PROGEN
Prostatype Genomics AB
0.16
-0.13
-45.14%
SE:IMMNOV
Immunovia AB
0.14
-0.37
-72.37%
SE:QLINEA
Q-linea AB
18.45
-28.70
-60.87%
SE:ACARIX
Acarix AB
0.24
-0.04
-14.29%
SE:BIOVIC.B
Biovica International AB Class B
0.43
-0.21
-32.92%
SE:DVYSR
Devyser Diagnostics AB
60.00
-92.20
-60.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.